Effects of herbal Epimedium on the improvement of bone metabolic disorder through the induction of osteogenic differentiation from bone marrow-derived mesenchymal stem cells

Kim,Do  Rim; Lee,Ji  Eun; Shim,Kyung  Jun; Cho,Jin  Hyoung; Lee,Ho  Chul; Park,Seong  Kyu; Chang,Mun  Seog

doi:10.3892/mmr.2016.6015

Effects of herbal Epimedium on the improvement of bone metabolic disorder through the induction of osteogenic differentiation from bone marrow-derived mesenchymal stem cells

Authors:
- Do Rim Kim
- Ji Eun Lee
- Kyung Jun Shim
- Jin Hyoung Cho
- Ho Chul Lee
- Seong Kyu Park
- Mun Seog Chang
View Affiliations

Affiliations: Department of Prescriptionology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
Published online on: December 9, 2016 https://doi.org/10.3892/mmr.2016.6015
Pages: 125-130
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Herbal Epimedium (HE) has been commonly used as a tonic, antirheumatic agent and in the treatment of bone‑associated diseases including osteoporosis. Treatment for osteoporosis is important to increase bone mass density and maintain to balance of bone remodeling. The present study was performed to investigate the effects of HE on mouse bone marrow mesenchymal stem cell (mBMMSC) proliferation and osteogenic differentiation, using MTT assays, proliferating cell nuclear antigen (PCNA) detection and apoptosis and differentiation assays. HE was demonstrated to inhibit the proliferation of mBMMSCs up to 45.43±3.33% and to decrease the level of PCNA expression compared with untreated cells. HE also induced late apoptosis at 24 and 48 h after treatment up to 71.93 and 67.03%, respectively, while only 14.93% of untreated cells exhibited apoptosis. By contrast, HE induced differentiation of mBMMSCs into an osteogenic lineage at the beginning of three weeks after commencement of treatment. This suggested that HE is a candidate as an inducer of osteogenesis from bone marrow mesenchymal stem cells, and additionally has potential for use in the treatment of bone metabolic disorders such as osteoporosis.

View Figures

View References

1	Gennari L, Rotatori S, Bianciardi S, Gonnelli S, Nuti R and Merlotti D: Appropriate models for novel osteoporosis drug discovery and future perspectives. Expert Opin Drug Discov. 10:1201–1216. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sambrook P and Cooper C: Osteoporosis. Lancet. 17:2010–2018. 2006.
3	Arceo-Mendoza RM and Camacho P: Prediction of fracture risk in patients with osteoporosis: A brief review. Womens Health (Lond Engl). 11:477–482. 2015. View Article : Google Scholar
4	Iñiguez-Ariza NM and Clarke BL: Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas. 82:245–255. 2015. View Article : Google Scholar : PubMed/NCBI
5	Mikami Y, Matsumoto T, Kano K, Toriumi T, Somei M, Honda MJ and Komiyama K: Current status of drug therapies for osteoporosis and the search for stem cells adapted for bone regenerative medicine. Anat Sci Int. 89:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
6	Vitale AM, Wolvetang E and Mackay-Sim A: Induced pluripotent stem cells: A new technology to study human diseases. Int J Biochem Cell Biol. 43:843–846. 2011. View Article : Google Scholar : PubMed/NCBI
7	Tögel F and Westenfelder C: Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn. 236:3321–3331. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hentze H, Graichen R and Colman A: Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotechnol. 25:24–32. 2007. View Article : Google Scholar : PubMed/NCBI
9	Chamberlain G, Fox J, Ashton B and Middleton J: Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 25:2739–2749. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, Kikuchi Y, Ito T, Okada T, Urabe M, et al: Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun. 30:121–127. 2008. View Article : Google Scholar : PubMed/NCBI
11	Jethva R, Otsuru S, Dominici M and Horwitz EM: Cell therapy for disorders of bone. Cytotherapy. 11:3–17. 2009. View Article : Google Scholar : PubMed/NCBI
12	Van Damme A, Driessche T Vanden, Collen D and Chuah MK: Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther. 2:195–209. 2002. View Article : Google Scholar : PubMed/NCBI
13	Yan FF, Liu Y, Liu YF and Zhao YX: Herba epimedii water extract elevates estrogen level and improves lipid metabolism in postmenopausal women. Phytother Res. 22:1224–1228. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sze SC, Tong Y, Ng TB, Cheng CL and Cheung HP: Herba epimedii: Anti-oxidative properties and its medical implications. Molecules. 15:7861–7870. 2010. View Article : Google Scholar : PubMed/NCBI
15	Chen WF, Mok SK, Wang XL, Lai KH, Lai WP, Luk HK, Leung PC, Yao XS and Wong MS: Total flavonoid action of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. Br J Nutr. 105:180–189. 2011. View Article : Google Scholar : PubMed/NCBI
16	Nadri S and Soleimani M: Isolation murine mesenchymal stem cells by positive selection. In Vitro Cell Dev Biol Anim. 43:276–282. 2007. View Article : Google Scholar : PubMed/NCBI
17	Eslaminejad MB and Nadri S: Murine mesenchymal stem cell isolated and expanded in low and high density culture system: Surface antigen expression and osteogenic culture mineralization. In Vitro Cell Dev Biol Anim. 45:451–459. 2009. View Article : Google Scholar : PubMed/NCBI
18	Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A and Nikbin B: Aging of mesenchymal stem cells in vitro. BMC Cell Biol. 7:142006. View Article : Google Scholar : PubMed/NCBI
19	Yee AS, Paulson EK, McDevitt MA, Rieger-Christ K, Summerhayes I, Berasi SP, Kim J, Huang CY and Zhang X: The HBP1 transcriptional repressor and the p38 MAP kinase: Unlikely partners in G1 regulation and tumor suppression. Gene. 336:1–13. 2004. View Article : Google Scholar : PubMed/NCBI
20	Oliver L, Hue E, Rossignol J, Bougras G, Hulin P, Naveilhan P, Heymann D, Lescaudron L and Vallette FM: Distinct roles of Bcl-2 and Bcl-Xl in the apoptosis of human bone marrow mesenchymal stem cells during differentiation. PLoS One. 6:e198202011. View Article : Google Scholar : PubMed/NCBI
21	Napolitano MA, Cipollaro M, Cascino A, Melone MA, Giordano A and Galderisi U: Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells. J Cell Sci. 15:2904–2911. 2007.